Register Now: Does Your Pharmaceutical WMS Grow with You?
Feature|Videos|June 10, 2026

Simplifying and Improving Global Pharma Operations

Key Takeaways

  • Understand how combining stationary and in-transit temperature data into a single, product-level view can support faster and more informed release decisions across the pharmaceutical supply chain.
  • Recognize how applying individual stability budgets per product can reduce waste and minimize manual data assessment efforts.
SHOW MORE

Supply chain data across stationary and in-transit monitoring can accelerate product release and reduce waste for pharma companies.

Sponsored by Elpro

Christoph Bamert, Chief Sales Officer at Elpro, explains safeguarding pharmaceutical products throughout the entire supply chain by providing visibility across both stationary and in-transit monitoring stages. By aggregating temperature and stability data in one place, pharma companies can see into a single, product-level view. Tracking individual stability budgets per product rather than applying strict alarms broadly accelerates release processes and reduce unnecessary quarantine times. Ambient temperature monitoring of the outside of passive packaging has emerged as a particularly valuable tool for identifying lane risks, delays, and whether products remain in controlled environments. The industry is shifting from traditional monitoring toward a data-driven approach that enables automated, product-based release decisions across the full pharmaceutical journey.


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.